Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Rukobia (fostemsavir) is a prescription medication

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155038
(Total Views: 494)
Posted On: 10/08/2024 6:53:23 PM
Posted By: My69z
Rukobia (fostemsavir) is a prescription medication used to treat HIV-1 infection in adults with multidrug-resistant HIV-1. It's taken orally in combination with other HIV medicines when standard combinations aren't effective:

How it works
Rukobia attaches to a protein on the HIV-1 virus, preventing it from interacting with T cells and reproducing. This slows the spread of infection.

When it's used
Rukobia is used when other antiretrovirals (ARVs) aren't effective due to resistance, intolerance, or safety concerns.

How it's taken
Rukobia is taken orally as a prolonged-release tablet, with a dose of 600 mg twice daily.

Side effects
Serious side effects include unexplained weight loss, severe tiredness, muscle aches, severe headaches, joint pain, numbness or tingling, vision changes, and signs of infection. Other side effects include heart rhythm problems and changes in liver function.

Immune Reconstitution Syndrome, which can include autoimmune disorders
____
https://medicine.yale.edu/news/yale-medicine-...ainst-hiv/
____

Although being a pill combo after all failed antiretrovirals, hats off to Dr. Lataillade for having designed a 1st @ BSM & leading a multi-country trial, to FDA approval.

Rukobia just does not perform even close to LL's level.
Of course the safety comparisons are also just a world of differences.

Two days ago Cytodyn said looking to possibly end needing antiretroviral. My guess is today is for pulling LL HIV into either ViiV or one of the other 2 BP's.

Rights to all Cytodyn's, LL-HIV based projects.

Including a re-filing of BLA.
This time also done right @ multiple countries.

Multiple forms of milestone payments to Cytodyn, later replaced with royalties from all HIV product lines.

Shall see.....



(6)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us